0JV0 Stock Chart & Stats
€1.08
€0.03(2.86%)
At close: 4:00 PM EDT
€1.08
€0.03(2.86%)
Day’s Range― - ―
52-Week Range€0.62 - €2.62
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€67.83M
Enterprise Value€11.63
Total Cash (Recent Filing)€88.04M
Total Debt (Recent Filing)€2.20M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding60,853,560
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.12
Price to Sales (P/S)1821.05
P/FCF Ratio-7.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.01Price Target Upside363.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€24.88K
Bulls Say, Bears Say
Bulls Say
Obesity Pipeline StrategyThe expanded obesity and cardiometabolic strategy gives iBio a defined development focus and multiple candidates rather than a single-asset story. Planned IND-equivalent filings, clinical starts, and interim data could create several opportunities to establish differentiated positioning over the next several quarters.
Promising Preclinical IBIO-610 DataThe primate results provide meaningful evidence for IBIO-610’s proposed differentiation, including durable pathway suppression, fat-selective weight loss, and lean-mass preservation. If replicated in clinical development, these attributes could support standalone use or combination potential in a competitive obesity market.
Low Current LeverageVery low debt relative to equity limits immediate balance-sheet pressure and reduces the burden of interest or debt repayment while the pipeline is developed. This provides more financial flexibility than a highly leveraged structure, although it does not eliminate the company’s need to fund ongoing losses.
Bears Say
Minimal And Declining RevenueRevenue remains too small to demonstrate commercial traction or meaningfully support the operating structure, while the sharp year-over-year decline points to limited current business scale. Until pipeline programs generate partnering, milestone, or product revenue, growth depends primarily on advancing uncommercialized assets.
Persistent Cash BurnMaterially negative operating and free cash flow shows that iBio is consuming cash to sustain operations and advance its programs. Because free cash flow remains negative despite reported improvement, the company will likely require continued financing or other capital sources to maintain development over the medium term.
Deep Operating And Net LossesThe scale of operating and net losses shows that costs substantially exceed the company’s very limited revenue base, leaving no evidence of near-term profitability. Continued losses can constrain internal investment capacity and increase reliance on external funding while clinical programs remain pre-commercial.
Ibio News
0JV0 FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was €0.61 and its highest was €2.62 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is €67.83M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Nov 17, 2026 which is in 57 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Aug 28, 2026. The company reported -€0.044 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.017.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 60,853,560 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -€0.044 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -2.205%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in DE:0JV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.01 (363.70% Upside)
€5.01 (363.70% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
327.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
0JV0 Stock 12 Month Forecast
Average Price Target
€5.01
▲(363.70% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―